Nuveen LLC Purchases Shares of 2,336,628 AMNEAL PHARMACEUTICALS, INC. $AMRX

Key Points

• Nuveen LLC has acquired a new position in Amneal Pharmaceuticals, investing approximately $19.58 million for 2,336,628 shares, representing 0.75% ownership of the company.
• Multiple institutional investors, including Vanguard Group Inc. and Dimensional Fund Advisors, have significantly increased their holdings in Amneal Pharmaceuticals, indicating growing confidence in the company.
• Analysts project growth for Amneal, with a consensus buy rating and an average price target of $11.60, suggesting potential upside for investors.

Nuveen LLC bought a new stake in AMNEAL PHARMACEUTICALS, INC. (NASDAQ:AMRX - Free Report) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 2,336,628 shares of the company's stock, valued at approximately $19,581,000. Nuveen LLC owned approximately 0.75% of AMNEAL PHARMACEUTICALS at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Janney Montgomery Scott LLC increased its holdings in AMNEAL PHARMACEUTICALS by 26.9% in the first quarter. Janney Montgomery Scott LLC now owns 19,350 shares of the company's stock valued at $162,000 after buying an additional 4,100 shares in the last quarter. Allspring Global Investments Holdings LLC increased its holdings in AMNEAL PHARMACEUTICALS by 53.4% in the first quarter. Allspring Global Investments Holdings LLC now owns 60,567 shares of the company's stock valued at $508,000 after buying an additional 21,079 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in AMNEAL PHARMACEUTICALS by 45.7% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 318,420 shares of the company's stock valued at $2,522,000 after buying an additional 99,866 shares in the last quarter. California State Teachers Retirement System increased its stake in shares of AMNEAL PHARMACEUTICALS by 10.3% during the 4th quarter. California State Teachers Retirement System now owns 131,713 shares of the company's stock worth $1,043,000 after purchasing an additional 12,282 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its stake in shares of AMNEAL PHARMACEUTICALS by 209.2% during the 4th quarter. BNP Paribas Financial Markets now owns 168,194 shares of the company's stock worth $1,332,000 after purchasing an additional 113,796 shares in the last quarter. 31.82% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

AMRX has been the subject of a number of recent research reports. Wall Street Zen cut shares of AMNEAL PHARMACEUTICALS from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, May 13th. The Goldman Sachs Group initiated coverage on shares of AMNEAL PHARMACEUTICALS in a research note on Friday, June 6th. They set a "buy" rating and a $12.00 price objective for the company. Five analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, AMNEAL PHARMACEUTICALS currently has an average rating of "Buy" and an average price target of $11.60.

Insider Buying and Selling at AMNEAL PHARMACEUTICALS

In other AMNEAL PHARMACEUTICALS news, EVP Andrew S. Boyer sold 279,244 shares of AMNEAL PHARMACEUTICALS stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $9.38, for a total value of $2,619,308.72. Following the transaction, the executive vice president owned 152,426 shares in the company, valued at $1,429,755.88. This trade represents a 64.69% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Jason B. Daly sold 22,000 shares of AMNEAL PHARMACEUTICALS stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $9.05, for a total transaction of $199,100.00. Following the completion of the transaction, the executive vice president owned 10,606 shares in the company, valued at approximately $95,984.30. This trade represents a 67.47% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 577,206 shares of company stock worth $5,405,265 in the last quarter. 17.45% of the stock is owned by insiders.

AMNEAL PHARMACEUTICALS Price Performance

AMRX stock traded down $0.31 during midday trading on Monday, hitting $9.28. The stock had a trading volume of 1,111,483 shares, compared to its average volume of 1,726,976. The firm has a market cap of $2.91 billion, a PE ratio of 928.93 and a beta of 1.11. AMNEAL PHARMACEUTICALS, INC. has a 12-month low of $6.68 and a 12-month high of $9.79. The company's 50-day moving average price is $8.40 and its 200 day moving average price is $8.02.

AMNEAL PHARMACEUTICALS (NASDAQ:AMRX - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported $0.23 EPS for the quarter, topping the consensus estimate of $0.17 by $0.06. AMNEAL PHARMACEUTICALS had a net margin of 0.12% and a negative return on equity of 189.49%. AMNEAL PHARMACEUTICALS has set its FY 2025 guidance at 0.700-0.750 EPS. As a group, sell-side analysts anticipate that AMNEAL PHARMACEUTICALS, INC. will post 0.53 EPS for the current year.

AMNEAL PHARMACEUTICALS Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.